ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.

ABSTRACT:

Objectives

To systematically evaluate the efficacy and safety of anaplastic lymphoma kinase (ALK) inhibitors in ALK-rearranged positive non-small cell lung cancer (NSCLC) with brain metastases, and update the overall survival (OS) outcomes of the second-generation and third-generation ALK (ALK-2^ndG/3^rdG) inhibitors versus first-generation (ALK-1^stG) inhibitors.

Design

The study is in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. Randomised controlled trials (RCTs) published up to 3 November 2021 were retrieved from PubMed, EMBASE, Cochrane Library and ClinicalTrials.gov.

Setting

RCTs from any country and healthcare setting.

Participants

Patients with advanced ALK-positive NSCLC

SUBMITTER: Jiang J 

PROVIDER: S-EPMC9486327 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature